OXI-4503 Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413251

CAS#: 288847-35-8 (free base)

Description: OXI-4503 Free Base is a diphosphate prodrug of cambretastatin A1.


Chemical Structure

img
OXI-4503 Free Base
CAS# 288847-35-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413251
Name: OXI-4503 Free Base
CAS#: 288847-35-8 (free base)
Chemical Formula: C18H22O12P2
Exact Mass: 492.06
Molecular Weight: 492.310
Elemental Analysis: C, 43.92; H, 4.50; O, 39.00; P, 12.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 288847-35-8 (free acid)   288847-34-7 (sodium)   1014615-46-3 (potassium)    

Synonym: OXI-4503; OXI 4503; OXI4503

IUPAC/Chemical Name: 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen phosphate)

InChi Key: GSOXMQLWUDQTNT-WAYWQWQTSA-N

InChi Code: InChI=1S/C18H22O12P2/c1-25-13-8-7-12(16(29-31(19,20)21)18(13)30-32(22,23)24)6-5-11-9-14(26-2)17(28-4)15(10-11)27-3/h5-10H,1-4H3,(H2,19,20,21)(H2,22,23,24)/b6-5-

SMILES Code: COC1=C(OC)C(OC)=CC(/C=C\C2=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(OC)C=C2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 492.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 2002 May-Jun;22(3):1453-8. Erratum in: Anticancer Res. 2003;23:5369. PMID: 12168822.

2: Chan LS, Daruwalla J, Christophi C. Selective targeting of the tumour vasculature. ANZ J Surg. 2008 Nov;78(11):955-67. doi: 10.1111/j.1445-2197.2008.04712.x. PMID: 18959693.

3: Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004 Jan 15;10(2):415-27. doi: 10.1158/1078-0432.ccr-0642-03. PMID: 14760060.

4: Cai SX. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. doi: 10.2174/157489207779561462. PMID: 18221055.

5: Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 2009 Oct 1;69(19):7524-8. doi: 10.1158/0008-5472.CAN-09-0381. Epub 2009 Sep 8. PMID: 19738066; PMCID: PMC2758166.

6: Johnson SP, Ogunlade O, Lythgoe MF, Beard P, Pedley RB. Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors. Clin Cancer Res. 2019 Dec 15;25(24):7436-7447. doi: 10.1158/1078-0432.CCR-19-0360. Epub 2019 Sep 24. PMID: 31551349.

7: Quatrale AE, Porcelli L, Gnoni A, Numico G, Paradiso A, Azzariti A. New vascular disrupting agents in upper gastrointestinal malignancies. Curr Med Chem. 2014;21(8):1039-49. doi: 10.2174/09298673113209990233. PMID: 23992324.

8: Cogle CR, Collins B, Turner D, Pettiford LC, Bossé R, Hawkins KE, Beachamp Z, Wise E, Cline C, May WS, Moreb JS, Hsu J, Hiemenz J, Brown R, Norkin M, Wingard JR, Uckun F. Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. Br J Haematol. 2020 Jun;189(5):e211-e213. doi: 10.1111/bjh.16629. Epub 2020 Apr 1. PMID: 32236943.

9: Wittenborn TR, Horsman MR. Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy. Acta Oncol. 2015;54(9):1385-92. doi: 10.3109/0284186X.2015.1064162. Epub 2015 Sep 2. PMID: 26329662.

10: d'Esposito A, Sweeney PW, Ali M, Saleh M, Ramasawmy R, Roberts TA, Agliardi G, Desjardins A, Lythgoe MF, Pedley RB, Shipley R, Walker-Samuel S. Computational fluid dynamics with imaging of cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours. Nat Biomed Eng. 2018 Oct;2(10):773-787. doi: 10.1038/s41551-018-0306-y. Epub 2018 Oct 10. PMID: 31015649.